STOCKWATCH: Suits in suites look to deal better hands in 2014
This article was originally published in Scrip
As the great and the good of the healthcare world (as well as the rest of us) descend on San Francisco for the annual JP Morgan Healthcare conference from 13-16 January, the focus of attention may not be on the companies' formal presentations. In 2014, the most interesting meetings will be the ones you are not invited to, those that are held in the hotel suites within four or five blocks of Union Square.
You may also be interested in...
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.
Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.
Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.